The BARD score and the NAFLD fibrosis score in the assessment of advanced liver fibrosis in nonalcoholic fatty liver disease

Medical Science Monitor

Volumn 18, Issue 12, 2012, Pages

  Cichoz Lach, Halina ^a   Celiński, Krzysztof ^a   Prozorow Król, Beata ^a   Swatek, Jarosław ^a   Słomka, Maria ^a   Lach, Tomasz ^a  

^a MEDICAL UNIVERSITY OF LUBLIN   (Poland)

Author keywords

BARD score; Liver biopsy; Liver fibrosis; NAFLD fibrosis score; Non alcoholic fatty liver disease

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; HEMOGLOBIN A1C;

ADULT; ARTICLE; BAFLD FIBROSIS SCORE; BARD SCORE; BODY MASS; DIAGNOSTIC TEST ACCURACY STUDY; FEMALE; HUMAN; HUMAN TISSUE; LIVER BIOPSY; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; NONALCOHOLIC FATTY LIVER; NONALCOHOLIC FATTY LIVER DISEASE ACTIVITY SCORE; OUTCOME ASSESSMENT; PREDICTIVE VALUE; RISK FACTOR; SENSITIVITY AND SPECIFICITY;

ADULT; DIAGNOSTIC TESTS, ROUTINE; FATTY LIVER; FEMALE; HUMANS; LIVER CIRRHOSIS; MALE; RISK FACTORS;

EID: 84874778141     PISSN: 12341010     EISSN: 16433750     Source Type: Journal    
DOI: 10.12659/MSM.883601     Document Type: Article

References (39)

1. Armstrong MJ, Houlihan DD, Bentham L et al: Presence and severity of non-alcoholic fatty liver disease in a large prospective primary care cohort. J Hepatol, 2012; 56: 234-40
2. Browning JD, Szczepaniak LS, Dobbins R et al: Prevalance of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology, 2004; 40: 1387-95
3. Wieckowska A, Feldstein AE: Diagnosis of nonalcoholic fatty liver disease: invasive versus noninvasive. Semin Liver Dis, 2008; 28: 386-95
4. Das K, Das K, Mukherjee PS et al: Nonobese population in a developing country has a high prevalence of nonalcoholic fatty liver and significant liver disease. Hepatology, 2010; 51: 1593-602
5. Nomura H, Kashiwagi S, Hayashi J et al: Prevalence of fatty liver disease in a general population of Okinawa, Japan. Japn J Med, 1998; 27: 142-49
6. Bedogni G, Miglioli L, Masutti F et al: Prevalence of and risk foactors for nonalcoholic liver disease. The Dyonisos nutrition and liver study. Hepatology, 2005; 42: 44-52
7. Adams LA, Feldstein AE: Non-invasive diagnosis of nonalcoholic fatty liver and nonalcoholic steatohepatitis. Dig Dis, 2011; 12: 10-16
8. Estep JM, Birerdinc A, Younossi Z: Non-invasive diagnostic tests for nonalcoholic fatty liver disease. Curr Mol Med, 2010; 10: 166-72
9. Sanyal AJ, Banas C, Sargeant C et al: Similarities and differences in outcomes of cirrhosis due to nonalcoholic steatohepatitis and hepatitis C. Hepatology, 2006; 43: 682-89
10. Bugianesi E, Leone N, Vanni E et al: Expanding the natural history of nonalcoholic steatohepatitis from cryptogenic cirrhosis to hepatocellular carcinoma. Gastroenterology, 2002; 123: 134-40
11. Marrero JA, Fontana RJ, Su GL et al: NAFLD may be a common underlying liver disease in patients with hepatocellular carcinoma in the United States. Hepatology, 2002; 36: 1349-54
12. Farrell GC, Larter CZ: Nonalcoholic fatty liver disease: from steatosis to cirrhosis. Hepatology, 2006; 43: S99-112
13. Lu P, Liu H, Yin H, Yang L: Expression of angiotensinogen during hepatic fibrogenesis and its effect on hepatic stellate cells. Med Sci Monit, 2011; 17(9): BR248-56
14. Colak Y, Ozturk O, Senates E et al: SIRT1 as a potential therapeutic target for treatment of nonalcoholic fatty liver disease. Med Sci Monit, 2011; 17(5): HY5-9
15. Vizzutti F, Arena U, Nobili V et al: Non-invasive assessment of fibrosis in non-alcoholic fatty liver disease. Ann Hepatol, 2009; 8: 89-94
16. Vuppalanchi R, Chalasani N: Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis: Selected practical issues in their evaluation and management. Hepatology, 2009; 49: 306-17
17. Ratziu V, Charlotte F, Heurtier A et al: Sampling variability of liver biopsy in nonalcoholic fatty liver disease. Gastroenterology, 2005; 128: 1898-906
18. Merriman RB, Ferrell LD, Patti MG et al: Correlation of paired liver biopsies in morbidly obese patients with suspected nonalcoholic fatty liver disease. Hepatology, 2006; 44: 874-80
19. Pais R, Lupşor M, Poantǎ L et al: Liver biopsy versus noninvasive methods-fibroscan and fibrotest in the diagnosis of non-alcoholic fatty liver disease: a review of the literature. Rom J Intern Med, 2009; 47: 331-40
20. Harrison SA, Oliver D, Arnold HL et al: Development and validation of a simple NALFD clinical scoring system for identifying patient without advanced disease. Gut, 2008; 57: 1441-47
21. Angulo P, Hui JM, Marchesini G et al: The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD. Hepatology, 2007; 45: 846-54
22. Guha IN, Parkes J, Roderick P et al: Noninvasive markers of fibrosis in nonalcoholic fatty liver disease: validating the European Liver Fibrosis Panel and exploring simple markers. Hepatology, 2008; 47: 455-60
23. Dixon JB, Bhathal PS, O'Brien PE: Nonalcoholic fatty liver disease: predictors of nonalcoholic steatohepatitis and liver fibrosis in the severely obese. Gastroenterology, 2001; 121: 91-100
24. Palekar NA, Naus R, Larson SP et al: Clinical model for distinguishing nonalcoholic steatohepatitis from simple steatosis in patients with nonalcoholic fatty liver disease. Liver Int, 2006; 26: 151-56
25. Ratziu V, Giral P, Charlotte F et al: Liver fibrosis in overweight patients. Gastroenterology, 2000; 118: 1117-23
26. Gholam PM, Flancbaum L, Machan JT et al: Nonalcoholic fatty liver disease in severely obese subjects. Am J Gastroenterol, 2007; 102: 399-408
27. Miyaaki H, Ichikawa T, Nakao K et al: Clinicopathological study of nonalcoholic fatty liver disease in Japan: the risk factors for fibrosis. Liver Int, 2008; 28: 519-24
28. Kleiner DE, Brunt EM, Natta MV et al: Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology, 2005; 41: 1313-21
29. Tiniakos DG: Nonalcoholic fatty liver disease/nonalcoholic steatohepatitis: histological diagnostic criteria and scoring systems. Eur J Gastroenterol Hepatol, 2010; 22: 643-50
30. Wieckowska A, McCullough AJ, Feldstein AE: Noninvasive diagnosis and monitoring of nonalcoholic steatohepatitis: present and future. Hepatology, 2007; 46: 582-89
31. McPherson S, Stewart SF, Henderson E et al: Simple non-invasive fibrosis scoring systems can reliably exclude advanced fibrosis in patients with non-alcoholic fatty liver disease. Gut, 2010; 59: 1265-69
32. Raszeja-Wyszomirska J, Szymanik B, Ławniczak M et al: Validation of the BARD scoring system in Polish patients with nonalcoholic fatty liver disease (NAFLD). BMC Gastroenterol, 2010; 10: 67
33. Wong VW, Wong GL, Chim AM et al: Validation of the NAFLD fibrosis score in a Chinese population with low prevalence of advanced fibrosis. Am J Gastroenterol, 2008; 103: 1682-88
34. Ruffillo G, Fassio E, Alvarez E et al: Comparison of NAFLD fibrosis score and BARD score in predicting fibrosis in nonalcoholic fatty liver disease. J Hepatol, 2011; 54: 160-63
35. Shah AG, Lydecker A, Murray K et al: Comparison of noninvasive markers of fibrosis in patients with nonalcoholic fatty liver disease. Clin Gastroterol Hepatol, 2009; 10: 1104-12
36. Yoneda M, Yoneda M, Mawatari H et al: Noninvasive assessment of liver fibrosis by measurement of stiffness in patients with nonalcoholic fatty liver disease (NAFLD). Dig Liv Dis, 2008; 40: 371-78
37. De Ledinghen V, Vergniol J, Foucher J et al: Feasibility of liver transient elastography with FibroScan using a new probe for obese patients. Liver Int, 2010; 30: 1043-48
38. Ong JP, Elariny H, Collantes R et al: Predictors of nonalcoholic steatohepatitis and advanced fibrosis in morbidly obese patients. Obes Surg, 2005; 15: 310-15
39. Uslusoy HS, Nak SG, Gulten M: Noninvasive predictors for liver fibrosis in patients with nonalcoholic steatohepatitis. World J Hepatol, 2011; 3: 219-27